The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
Abstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of b...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | BMC Pregnancy and Childbirth |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12884-021-04246-x |
| _version_ | 1818824036625416192 |
|---|---|
| author | Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili |
| author_facet | Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili |
| author_sort | Yas Arimi |
| collection | DOAJ |
| description | Abstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008, RR = 1.59 95% CI (1.12–2.27)) and requiring more respiratory support (71% versus 50%, p = 0.002, RR = 1.43 95% CI (1.13–1.80)) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support. |
| first_indexed | 2024-12-18T23:49:29Z |
| format | Article |
| id | doaj.art-26e47b3783b34c219ce623d48f76dbe4 |
| institution | Directory Open Access Journal |
| issn | 1471-2393 |
| language | English |
| last_indexed | 2024-12-18T23:49:29Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pregnancy and Childbirth |
| spelling | doaj.art-26e47b3783b34c219ce623d48f76dbe42022-12-21T20:47:02ZengBMCBMC Pregnancy and Childbirth1471-23932021-11-012111510.1186/s12884-021-04246-xThe effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestationYas Arimi0Narges Zamani1Mamak Shariat2Hossein Dalili3Resident of Obstetrics and Gynecology, Maternal Fetal Neonatal Researsh Center, Tehran University of Medical SciencesDepartment of Obstetrics and Gynecology, Vali-e-Asr Hospital, Tehran University of Medical SciencesMaternal, Fetal & Neonatal Research Center-Breastfeeding Research Center, Tehran University of Medical SciencesBreastfeeding Research Center, Vali-e-Asr Hospital, Tehran University Of Medical SciencesAbstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008, RR = 1.59 95% CI (1.12–2.27)) and requiring more respiratory support (71% versus 50%, p = 0.002, RR = 1.43 95% CI (1.13–1.80)) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.https://doi.org/10.1186/s12884-021-04246-xBetamethasoneLate pretermNeonatal outcome |
| spellingShingle | Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation BMC Pregnancy and Childbirth Betamethasone Late preterm Neonatal outcome |
| title | The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| title_full | The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| title_fullStr | The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| title_full_unstemmed | The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| title_short | The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| title_sort | effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation |
| topic | Betamethasone Late preterm Neonatal outcome |
| url | https://doi.org/10.1186/s12884-021-04246-x |
| work_keys_str_mv | AT yasarimi theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT nargeszamani theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT mamakshariat theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT hosseindalili theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT yasarimi effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT nargeszamani effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT mamakshariat effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT hosseindalili effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation |